The Oncology Institute, Inc. (NASDAQ:TOI) Director Buys $94,184.48 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala bought 90,562 shares of the business’s stock in a transaction dated Wednesday, March 26th. The shares were bought at an average cost of $1.04 per share, for a total transaction of $94,184.48. Following the transaction, the director now owns 224,971 shares in the company, valued at approximately $233,969.84. The trade was a 67.38 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Oncology Institute Stock Up 2.7 %

NASDAQ TOI opened at $1.14 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91. The Oncology Institute, Inc. has a 52 week low of $0.13 and a 52 week high of $1.63. The firm has a market capitalization of $86.14 million, a price-to-earnings ratio of -1.46 and a beta of 0.41. The company has a fifty day moving average of $0.86 and a two-hundred day moving average of $0.48.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%. The firm had revenue of $100.27 million for the quarter, compared to analysts’ expectations of $109.15 million.

Institutional Investors Weigh In On Oncology Institute

Several hedge funds and other institutional investors have recently modified their holdings of TOI. FreeGulliver LLC grew its position in Oncology Institute by 219.3% in the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock valued at $186,000 after acquiring an additional 412,578 shares during the last quarter. Tiff Advisory Services LLC boosted its stake in shares of Oncology Institute by 13.2% during the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock valued at $921,000 after purchasing an additional 346,256 shares during the period. Virtu Financial LLC bought a new position in shares of Oncology Institute in the fourth quarter worth about $41,000. Jane Street Group LLC increased its stake in Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after buying an additional 109,769 shares during the period. Finally, HighTower Advisors LLC lifted its holdings in Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after buying an additional 53,382 shares in the last quarter. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.